News und Analysen

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q1 2024 Earnings CallApr 30, 2024, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Earnings season is officially here. As per usual, there have already been epic sell-offs and run-ups across well-known names.

However, long-term investors know that the best way to view a quarterly

Earnings season is officially here. As per usual, there have already been epic sell-offs and run-ups across well-known names.

However, long-term investors know that the best way to view a quarterly

So far, 2024 has been a year to forget for animal healthcare juggernaut Zoetis (NYSE: ZTS). Hit by the triple whammy of weak earnings, a formal investigation from the European Commission, and

I owned shares of Pfizer (NYSE: PFE) when the COVID-19 pandemic started. Watching the stock soar over 60% in roughly two years was fun. Seeing Pfizer's share price fall nearly 60% from its peak

I owned shares of Pfizer (NYSE: PFE) when the COVID-19 pandemic started. Watching the stock soar over 60% in roughly two years was fun. Seeing Pfizer's share price fall nearly 60% from its peak

The market isn't rational always and everywhere. Sometimes, shares of excellent companies with bright futures almost inexplicably fail to keep pace with broader equities. When that happens, it's

Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled

Viking Therapeutics (NASDAQ: VKTX) has been flying on all cylinders since the beginning of the year. The company's shares are up 246% due to excellent clinical progress. It's not rare for smaller

Last Friday, Agenus (NASDAQ: AGEN), an immuno-oncology player, saw its shares soar by a staggering 40.8%. This remarkable rally occurred seemingly without a clear catalyst. The company is set to

Income investors can be growth investors, too. Granted, it's not always easy to find stocks that pay generous dividends and offer solid prospects of share price appreciation. However, such stocks

Income investors can be growth investors, too. Granted, it's not always easy to find stocks that pay generous dividends and offer solid prospects of share price appreciation. However, such stocks

There are many dividend stocks on the market, but few are as prominent as AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). These companies have raised their payouts for over 50 consecutive

Nvidia has been an amazing stock to own over the past few years, generating incredible returns for investors. But the risk is that expectations may be too high for the stock, especially with respect

Nvidia has been an amazing stock to own over the past few years, generating incredible returns for investors. But the risk is that expectations may be too high for the stock, especially with respect

It's still early days in this latest earnings season, but it seems we can already tag one winner in the healthcare sector -- take a bow, UnitedHealth Group (NYSE: UNH).

As the season lurched into

It's still early days in this latest earnings season, but it seems we can already tag one winner in the healthcare sector -- take a bow, UnitedHealth Group (NYSE: UNH).

As the season lurched into

Buy, hold, rake in solid income. That sounds like a pretty good investing strategy. You only have to find the right stocks worthy of holding for the long term and that pay attractive dividends.

By almost any measure, AbbVie (NYSE: ABBV) shares should have risen Friday. The pharmaceutical giant delivered first-quarter sales and earnings results that topped estimates. The decline in sales of

Image source: The Motley Fool.

AbbVie (NYSE: ABBV)Q1 2024 Earnings CallApr 26, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Centene (NYSE: CNC)Q1 2024 Earnings CallApr 26, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com